Listened to and talked with Dr. Rubinfeld today. This is an

New Post Public Reply Private Reply Replies (0) Message Board
Natural Treasures
Listened to and talked with Dr. Rubinfeld today. This is an update and first hand account form one of the shareholders of AMBS and was posted on the AMBS board from the shareholders meeting today.

Posted By: barcode27

Update from ASM Meeting:

I arrived at the Wilson, Sonsini, Goodrich, and Rosati offices around 9:15 AM (saw Gerald going in the door up ahead of me). After navigating the construction zone in the lobby, I arrived on the 33rd floor and checked in with the receptionist. I could see Gerald, John, Marc Faerber, and a few others through the glass windows of a conference room directly ahead. All shareholders were being directed to wait in a room down the hall until the meeting began. It was a nice opportunity to visit with other shareholders. Robert Harris stuck his head in the door and thanked us all for coming at some point in there.

Just before 10 AM, Gerald came to our room and invited us to join him the main conference room. We all made informal introductions to the company personnel before the meeting began. Amarantus attendees were:

Gerald Commissiong
John Commissiong
Bob Farrell
Robert Harris
Marc Faerber
Joe Rubinfeld (was excited to see him there!)
Don Huffman
David Lowe

I counted 10 shareholders in attendance, including myself (may be off by one or two since we were all sitting along one side of a long table).

There was also an attendee from Marcum (didn't catch his name), and a representative of VStock Transfer was on the phone.

Gerald opened the meeting by reading from a pre-planned script regarding ground rules, participant roles, and the issues at hand which would be voted on. Bob Farrell took over and also read some of the scripted opening.

Gerald then walked through each item for vote with a brief explanation and paused to see if there were any formal questions regarding any of the issues. Hearing none, he stepped through this portion fairly quickly. Ballots were then distributed in the room to people who indicated they hadn't voted already.

Highlights from the voting portion:

As of today, there are 753.984M shares outstanding, and 748M of those shares were represented either in person or by proxy for this vote. All items passed according to the recommendations of the board (no surprise there). Gerald left the room to fax the in-person ballots to VStock, but I felt this was largely a symbolic move since he had already announced that each item had passed.

After the official meeting, Gerald said they everyone could stick around for informal discussion and mingling. Not a single person left the room, and I was very impressed at how attentive and engaged everyone from the company was. I especially noted Don Huffman and Robert Harris taking detailed notes on shareholder questions, concerns.

Shareholder question portion:

IMO, the most unfortunate/uncomfortable part of the meeting began when the first shareholder took the floor. If he posts on here, I'm sorry, but I doubt he does since he made it a point to say that he doesn't own a computer, cell phone, iPad, etc. He offered support for the company and said he was proud to be a shareholder, then began rambling for what seemed like forever suggesting that the company should pay 12-18 year old kids to do research projects. I couldn't really follow what he was saying, but most of it was nonsensical. He kept saying stuff like "Gerald, you don't have any experience and don't really know the biotech lingo, but your father does." He was pretty rude to Gerald and I thought it was way out of line. I won't go into more detail here, but needless to say I was glad when he yielded the floor.

Next came excellent questions on LymPro, specifically centered on the ICON deal. Gerald couldn't say too much, but I did note that he expects the arrangement with ICON to expand in scope in the future after the next set of results are released. Everyone in the room perked up when Joe Rubinfeld spoke up for the first time, emphasizing that we're ready to launch a diagnostic in 4 months... "we're there!"

I asked a question related to GDNF and MANF, specifically on how the ongoing GDNF trials in the UK might be able to provide some lift to the MANF PD effort. I noted the the amount of scientific literature published to date on GDNF seems to be 10 to 1 vs. MANF and asked if the company saw any reason for that. A good discussion then resulted with input from David Lowe and John Commissiong. John essentially said that "GDNF is an old drug" and that he fully expects a new flood of MANF research and published material over the next 2-3 as interest in neurotrophic factors has been resurrected after a sleepy decade. I asked David Lowe directly if he thought that in 10-15 years there would be a fragmented market between neurotrophic factors like GDNF, CDNF, MANF, etc, and he was emphatic that he thought MANF would become the leader eventually.

Other random notes from the question portion:

- Gerald mentioned a pre-IND meeting regarding MANF with the FDA in a "couple of days." Disclaimer: I may not have heard him right (maybe he meant a couple of weeks/months), but it's sitting right here in my notes and my ears perked up in the meeting when he said this. He then went on to discuss a fairly critical 60-120 day period when the company will have a back-and-forth dialogue with the FDA regarding their IND submission.

- Eltoprazine first patient dosing is possible this year, but to be conservative the company is targeting early 2015. Gerald mentioned again that Eltoprazine has already been in 700 patients, strong safety profile, etc.

- JC was asked if he liked the setup at QB3, if he had what he needed, etc. He said it was a good arrangement, and started to mention upcoming collaboration with different university teams. Gerald quickly stepped in and stopped him, saying that they weren't allowed to talk about that yet. Everyone had a good chuckle at that. He had some follow-on questions regarding PhenoGuard, and made note of the fact that not everyone can do this type of work (mentioned that you not only have to keep the neurons alive, but also keep them "connected". I don't know enought about the science to comment more on that, just reporting what he stated.

- There are no formal ties to Cerora, just that they like the company and have a strong belief in the founder's integrity (guessing this was referring to Adam Simon)

After the Q&A session everyone hung around for another half hour or so and talked one-on-one. I got to speak with Don Huffman and David Lowe extensively during this time, and also talked with Joe Rubinfeld briefly. Folks, these guys are dedicated to what they're doing and I was honored to be in the room talking with them. I was very impressed with the entire session and feel more strongly than ever that the company has assembled the right team at the right time and is poised to do Earth-shattering things.

I'm currently waiting at SFO airport for my flight back home but will be happy to answer any questions later tonight.

Read More: http://investorshangout.com/post/view?id=2048...z3E5apteV9

Amgen Inc. (AMGN) Stock Research Links

AMGN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 63

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Northstar's December Test: Metrics Over More Promises

Updated Category News Views 43

A shingle recycler earns its stripes when the machinery behaves, not when the slide deck does. Northstar Clean Technologies is putting Empower Calgary under a brighter light on December 1, pairing its third-quarter 2026 results with a comprehensive production update and a new set of operating metrics. For shareholders, especially those following OTCQB:ROOOF, this is the...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 73

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 81

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 60

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 105

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 115

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading

Top 5 Most Recently Viewed Articles

How a $100 Investment in Builders FirstSource Transformed

Updated Category News Views 173

Understanding Builders FirstSource's Growth Journey Investing in the stock market can sometimes feel daunting, but Builders FirstSource (NYSE: BLDR) has presented an impressive case for savvy investors over the last five years. This company has not only survived the ups and downs of the market but has also outperformed it significantly. With a remarkable 28.17% annualized...

Continue Reading
Adagene Strengthens Leadership with Axel Hoos as Advisor

Updated Category News Views 99

Adagene Appoints Renowned Immuno-Oncology Expert Adagene Inc. (Nasdaq: ADAG) has marked a significant milestone in its journey towards transforming cancer treatment by appointing Dr. Axel Hoos as an Executive Advisor. With an impressive background in immuno-oncology, Dr. Hoos brings a wealth of knowledge and experience that aligns perfectly with Adagene's mission....

Continue Reading
Suffolk County Transit Orders 132 Modern Buses from NFI

Updated Category News Views 122

NFI Group Inc. Awarded Contract for New Buses A recent agreement between NFI Group Inc. and Suffolk County Transit has been finalized, marking an essential step in modernizing the county's public transportation system. The contract, which spans five years, encompasses the delivery of up to 132 next-generation buses, including a combination of hybrid-electric and...

Continue Reading
Decoding Love: The Real Patterns of Relationships

Updated Category News Views 131

The Relationship Maze: More Than Meets the Eye Love ain't just a simple spark over a fancy dinner, let me tell you. In Dr. Bernadette Marson’s ‘The Relationship Code,’ she digs into seventy-seven elements gnawing at why relationships can crumble or thrive. It’s like a blueprint of human entanglements—a veritable explorer’s guide to the vast, wild creation we...

Continue Reading
Understanding BP's Recent Options Activity and Market Insights

Updated Category News Views 129

Understanding BP's Options Activity Investors with substantial capital have recently adopted a positive outlook on BP. This inspires interest among retail traders. Our analysis of publicly available options data indicates notable trading activity involving BP. An uptick of this nature often hints that informed investors anticipate significant developments regarding the...

Continue Reading